#Samples for healthcare professionals full
Please see full Prescribing Information, including Boxed Warning, for Lo Loestrin Fe.ġ. IQVIA® National Prescription Audit® - TRx/EUTRx Data: January 2019 – December 2019 (claim derived from the use of information under license from IQVIA, which expressly reserves all rights, including rights of copying, distribution, and republication).Ģ. Lo Loestrin® Fe prescribing information. Patients should be counseled that COCs do not protect against HIV infection (AIDS) and other sexually transmitted diseases. The most common adverse reactions (incidence ≥2%) were nausea/vomiting, headache, bleeding irregularities, dysmenorrhea, weight fluctuation, breast tenderness, acne, abdominal pain, anxiety, and depression.
#Samples for healthcare professionals trial
In the clinical trial for Lo Loestrin Fe, serious adverse reactions included deep vein thrombosis, ovarian vein thrombosis, and cholecystitis. Patients using Lo Loestrin Fe who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated. Women who are pre-diabetic or diabetic should be monitored while using Lo Loestrin Fe.Īlternate contraceptive methods should be considered for women with uncontrolled dyslipidemia. Lo Loestrin Fe should not be prescribed for women with uncontrolled hypertension or hypertension with vascular disease. If jaundice occurs, treatment should be discontinued. Lo Loestrin Fe should not be started any earlier than 4 weeks after delivery, in women who are not breastfeeding. Warnings and Precautionsĭiscontinue Lo Loestrin Fe if a thrombotic event occurs, and at least 4 weeks before and through 2 weeks after major surgery. Now or in the past, and in women using Hepatitis C drugs containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. (benign or malignant) or liver disease, undiagnosed abnormal uterine bleeding, or breast cancer or other estrogen- or progestin-sensitive cancer, Lo Loestrin Fe is contraindicated in pregnant patients, in women with a high risk of arterial or venous thrombotic diseases, liver tumors This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked.įor this reason, COCs should not be used by women who are over 35 years of age and smoke. Warning: cigarette smoking and serious cardiovascular eventsĬigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. The efficacy of Lo Loestrin Fe in women with a body mass index (BMI) of >35 kg/m 2 has not been evaluated. Lo Loestrin® Fe is an estrogen/progestin combination oral contraceptive (COC) indicated for use by women to prevent pregnancy.